Clinical Trials Directory

Trials / Completed

CompletedNCT03491748

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants

A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ETX0282 Administered in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
99 (actual)
Sponsor
Entasis Therapeutics · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This research project is being conducted to investigate the safety, tolerability, and pharmacokinetics (PK) of a single ascending dose (SAD) and multiple ascending doses (MAD) of oral ETX0282 when administered alone and in combination with cefpodoxime proxetil in healthy adult participants.

Detailed description

This Phase 1, single-center, double-blind, randomized, placebo-controlled study will be conducted to: * Determine the safety and tolerability of oral ETX0282 when administered as a SAD and MAD to healthy participants; * Determine the safety and tolerability of oral ETX0282 when administered as a single oral dose in combination with cefpodoxime proxetil to healthy participants; * Characterize the PK in plasma and in urine of ETX0282 and ETX1317 following administration of single and multiple oral doses of ETX0282 in healthy participants; and * Determine the PK profile in plasma and in urine of ETX0282 and ETX1317 and of cefpodoxime proxetil and cefpodoxime following administration of single oral doses of ETX0282 and cefpodoxime proxetil alone and when ETX0282 is co-administered with cefpodoxime proxetil at the same time as single oral doses in healthy participants.

Conditions

Interventions

TypeNameDescription
DRUGETX0282Oral Gelatin capsules
DRUGCefpodoxime proxetilOral tablets
DRUGPlaceboOral Gelatin capsules

Timeline

Start date
2018-03-16
Primary completion
2019-09-11
Completion
2019-09-11
First posted
2018-04-09
Last updated
2020-01-14

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT03491748. Inclusion in this directory is not an endorsement.